Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies
Shots:
- Ensoma to receive $100M in up front & preclinical research payment- $10M in equity investment- and is eligible to receive $1.25B as development and commercialization milestones along with royalties on sales of each product
- Takeda to get exclusive WW rights Ensoma’s Engenious vectors for up to five rare disease indications. Ensoma to conduct preclinical research activities for the Takeda programs- and both parties will share in responsibilities leading to the submission of IND applications. Takeda will lead development activities thereafter
- Additionally- Ensoma launches to next-generation in vivo approach to deliver first “off-the-shelf” genomic medicines with the $70M Series A funding
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com